仙灵骨葆联合钙剂治疗高龄患者老年性骨质疏松症的临床研究

目的：观察仙灵骨葆胶囊联合钙尔奇D和骨化三醇对高龄患者老年性骨质疏松症的治疗效果.方法：选择60例高龄老年性骨质疏松症患者随机分为两组,治疗组（仙灵骨葆＋钙尔奇D＋骨化三醇）30例,对照组（钙尔奇D＋骨化三醇）30例.观察两组患者治疗前后和两组间的VAS评分、SF-36评分、BMD、血Ca、血P、ALP、TRACP的差异.结果：两组治疗后VAS评分较治疗前均明显降低（P＜0.01）,治疗组降低较对照组更明显（P＜0.01）.两组治疗后SF-36评分较治疗前均明显提高（P＜0.01）,治疗组升高较对照组更明显（P＜0.01）.治疗组治疗后BMD明显升高,对照组BMD变化不大,两组比较有显著差异（P＜0.05）.治疗前后两组血Ca和血P均变化不大,组间比较无差异（P＞0.05）.治疗组治疗后ALP明显升高,对照组ALP变化不大,两组比较有显著差异（P＜0.05）.两组治疗后TRACP较治疗前均有所降低,治疗组降低明显,组间比较有显著差异（P＜0.01）,两组所有患者无严重不良反应发生.结论：仙灵骨葆胶囊联合钙尔奇D和骨化三醇治疗高龄患者老年性骨质疏松症效果确切,且安全性良好.

Clinical research of the treatment of primary osteoporosis in elder patient with combined use of Xianlinggubao and Calcium

Objective ： To observe the clinical efficacy of combined use of Xianlinggubao capsule and Caltrate with vitamin D tablets and Calcitriol soft capsule on primary osteoporosis in eider patient. Methods ：60 cases of elder patients with primary osteoporosis of elder patient were randomly divided into two groups using random number table, treatment group （ Xianlinggubao and Caltrate with vitamin D and Calcitriol） and control group （Cahrate with vitamin D and Calcitrio）. The VAS score, SF -36 score, bone and density（ BMD）, serum calcium, serum phosphorus, serum alkaline phosphatase（ ALP）, and serum tartrateresistant acid phosphatase （TRACP） were measured and compared before and after treatment between the treatment and control groups. Results： There were no serious adverse reaction occured in two groups. The VAS score in two groups decreased obviously after the treatment, with statistical significance（P 〈 0.01 ）, the treatment group significantly lower than control group （P 〈 0.01 ）. The SF -36 score in two groups increased obviously after the treatment, with statistical significance（P 〈 0.01 ）, the treatment group significantly higher than control group（ P 〈 0.01 ）. BMD in patients of treatment grouP increased after the treatment, however in the control group had no obvious change, compared with two groups had significant differences（ P 〈 0.05 ）. The differences of serum calcium and phosphate among the patients of two groups were not significant statistically before and after the treatment（P 〉 0.05 ）. ALP in patients of treatment group increased after the treatment, however in the control group had no obvious change, compared with two groups had significant differences （ P 〈 0.05 ）. TRACP in patients of two groups decreased after the treatment, the treatment group significantly lower than control group, with statistical significance（ P 〈 0.01 ）. Conclusions ： The clinical efficacy of combined use of Xianlinggubao capsule and Caltrate with vitamin D tablets and Calcitriol soft capsule on primary osteoporosis in elder patient is obvious and safe.